Discontinue Amena immediately—do not reduce the dose
When a patient on Amena (ethinyl estradiol + norethisterone) develops rising ALT and AST levels, the medication should be stopped completely, not dose-reduced. Combined hormonal contraceptives can cause drug-induced liver injury, and dose reduction is not an appropriate management strategy for hepatotoxicity.
Immediate Management
Stop Amena completely and recheck liver enzymes in 2 weeks 1. The threshold for concerning transaminase elevation is 3 times above the upper limit of normal 1. When abnormalities return to normal, you may consider restarting with close monitoring, though switching to an alternative contraceptive method is generally safer 1.
Key Clinical Considerations
Norethisterone-related hepatotoxicity is well-documented 2. Three case reports specifically describe norethisterone causing significant transaminase elevations in women taking it for prolonged periods, with complete resolution after drug withdrawal 2.
Combined oral contraceptives containing ethinyl estradiol and norethisterone can cause drug-induced liver injury 3. A biopsy-proven case demonstrated hepatotoxicity from a second-generation COC, confirmed by re-challenge testing 3.
The hepatotoxic effect appears related to both the estrogen and progestin components, with ethinyl estradiol showing marked enzyme elevations even at low doses 4.
Alternative Contraceptive Options
Once liver enzymes normalize, consider switching to:
- Progestin-only methods (microdose pills, implants, or levonorgestrel IUD) if hormonal contraception is still desired 5
- Copper IUD as a non-hormonal alternative
- Barrier methods if other options are unsuitable
Monitoring Protocol
If you restart any hormonal contraceptive after normalization:
- Measure ALT and AST at 4 weeks after restarting 1
- Continue monitoring every 3-6 months 1
- Permanently discontinue if transaminases rise again
Important Caveats
Do not attempt dose reduction as a management strategy. The evidence consistently shows that hepatotoxicity from combined hormonal contraceptives requires complete discontinuation 1, 2. The liver injury is not dose-dependent in a way that allows safe continuation at lower doses—it represents an idiosyncratic drug reaction requiring cessation.
Ensure adequate contraceptive coverage during the transition period to prevent unintended pregnancy while liver function recovers and alternative methods are initiated.